← NewsAll
TrumpRx: what it is and whether it can save you money
Summary
TrumpRx is a government-hosted website listing cash-only discounts for primarily name-brand prescription drugs; at launch it included 43 drugs from five manufacturers and showed discounts ranging about 33%–93%.
Content
The Trump administration launched TrumpRx in early February as a government-hosted website that lists discounted prices for prescription drugs. The platform shows mainly name-brand medications and displays prices for people paying with cash rather than through insurance. President Trump mentioned the program during the State of the Union and the administration said more drugs would be added in the coming months. At the time of publication, the site listed discounts from five manufacturers and showed 43 drugs.
Key details:
- The discounts on TrumpRx apply to customers paying cash; the site does not process purchases directly.
- To use a listed price, users must present a coupon at a participating pharmacy or follow a manufacturer link to the maker's ordering portal; a valid prescription is still required.
- At launch, five companies were participating: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, and 43 drugs were listed on TrumpRx.gov.
- The site excludes people using Medicare, Medicaid, Medigap, VA, DOD, TRICARE, and other specified state and federal assistance programs from the advertised savings.
- Listed discounts on the site range from about 33% to 93%, with many around the 50% range according to reporting and KFF’s comments.
- KFF’s analysis and reporting note that many of the same manufacturer discounts are also available directly on manufacturers’ websites and that other discount platforms offer broader selections, including generics.
Summary:
TrumpRx provides a searchable list of cash-only discounts for mostly name-brand prescription drugs and is most relevant to people paying out of pocket or those whose insurance does not cover specific drugs. The administration indicated more drugs would be added in coming months; whether and how the list expands is undetermined at this time.
